Gritstone bio Inc., entered into a clinical trial agreement with NCI to evaluate an autologous T-cell therapy expressing a T-cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate, SLATE-KRAS, in a phase I study. The study will be led by Steven A. Rosenberg, chief of the surgery branch at NCI’s Center for Cancer Research.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe